Bromocriptine Capsules and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Bromocriptine Capsules and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: bromocriptine
Brand name: Parlodel, Cycloset
Synonyms: Bromocriptine
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bromocriptine Capsules-Insulin glargine, recombinant Subcutaneous
- Bromocriptine Capsules-Insulin glulisine
- Bromocriptine Capsules-Insulin Glulisine (Cartridges and Pens)
- Bromocriptine Capsules-Insulin Glulisine (Vials)
- Bromocriptine Capsules-Insulin glulisine Subcutaneous
- Bromocriptine Capsules-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Bromocriptine Mesylate
- Insulin glargine and lixisenatide Subcutaneous-Brompheniramine
- Insulin glargine and lixisenatide Subcutaneous-Brompheniramine and codeine
- Insulin glargine and lixisenatide Subcutaneous-Brompheniramine and phenylephrine
- Insulin glargine and lixisenatide Subcutaneous-Brompheniramine and Phenylephrine Chewable Tablets
- Insulin glargine and lixisenatide Subcutaneous-Brompheniramine and Phenylephrine Liquid